Medical/Pharmaceuticals
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative ther...
2026-06-12 14:59
687
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab(AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-s...
2026-06-12 09:57
1648
Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-12 09:19
1622
KPJ Healthcare Launches First Kidney Transplant Service Within Its Hospital Network
Tawakkal Specialist Hospital expands access to kidney transplantation through coordinated specialist care KUALA LUMPUR, Malaysia, June 11, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") has launched its first Kidney Transplant Service within the KPJ network, marking...
2026-06-11 23:46
2365
Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congra...
2026-06-11 22:20
2770
ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
The new intraocular lens combines an aspheric bitoric optic with a patented non-constant aberration design (ZO optic) on a fully preloaded, hydrophobic c-Loop platform to help deliver excellent visual outcomes and long-term stability for patients. JENA, Germany, June 11, 2026 /PRNewswire/ -- ZEI...
2026-06-11 19:00
1592
Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The ...
2026-06-11 16:22
2268
Cynosure Lutronic's XERF™, Worldwide Adoption Accelerates, Now 3x Faster
Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North America leading the surge. SINGAPORE, June 11, 2026 /PRNewswire/ -- Cynosure Lutronic's XERF™, the world's first multifrequency monopolar R...
2026-06-11 14:39
2060
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Di...
2026-06-11 14:20
2215
Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were d...
2026-06-11 12:54
2558
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proo...
2026-06-11 10:56
2558
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-11 09:52
1932
Pantai Hospital Kuala Lumpur Launches AI-Powered Adaptive Radiotherapy System to Advance Personalised Cancer Care in Malaysia
Varian Ethos with HyperSight supports daily treatment adaptation, helping clinicians deliver more precise radiotherapy while reducing unnecessary exposure to healthy tissue KUALA LUMPUR, Malaysia, June 10, 2026 /PRNewswire/ -- Pantai Hospital Kuala Lumpur, part of the IHH Healthcare multination...
2026-06-11 08:41
2936
Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031
New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures LONDON, June 11, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Growth Opportunities in Global Pharmaceuti...
2026-06-11 04:56
1902
HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices
The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies. BOSTON and SUZHOU, China, June 10, 2026 /PRNewswire/ -- HkeyBio, a specialized preclinical CRO focused...
2026-06-10 21:16
3586
QingSong Health Corp (2661.HK) and Basel Medical Sign Strategic Cooperation Memorandum to Explore AI Healthcare Services in Southeast Asia
BEIJING, June 10, 2026 /PRNewswire/ -- Recently, QingSong Health Corp (2661.HK) andBasel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties intend to explore cooperation in AI-enabled healthcare services, insurance-related healthcare solutions, and c...
2026-06-10 21:05
4074
Vatech Completes Full-Portfolio EU MDR Certification
Certification covers all three dental imaging categories and every 2026 model launch HWASEONG, South Korea, June 10, 2026 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global leader in dental imaging, today announced the completion of EU Medical Device Regulation (MDR; Regulation (EU) 2017/745) cer...
2026-06-10 21:00
2193
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medic...
2026-06-10 20:00
1721
Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points * Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic e...
2026-06-10 17:00
1875
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
* Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world. * Servier strengthens its commitment to rare neurologic...
2026-06-10 16:00
1898
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16
Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 297 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
11629
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
10030
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
2026-06-05 21:13
9929
